The first russian darbepoetin alfa bioanalogue: results of a double-blind, randomized clinical study of efficacy and safety for patients with nephrogenic anemia on programmed hemodialysis
- Authors: Shilo V.Y.1,2, Babich V.P3, Vasilieva G.V4, Vishnevsky K.A5, Gomova T.A6, Doru-Tovt V.P7, Dudarev M.V8, Yeremeeva L.F9,10, Zuev A.V11, Kotova L.I12, Novoseltsev I.L13, Rodoman G.V14, Ryasnyansky V.Y.15, Sabodash A.B16, Solovyova A.V17, Solovyova O.M18, Suchkov V.N19, Strokov A.G20, Timokhovskaya G.Y.21, Chistyakov V.M22, Shpagina L.A23,24, Fedotova L.A25, Khadikova N.G26, Khazova E.V27, Morozova M.A28, Dokukina E.A28, Lin’kov Y.N28
-
Affiliations:
- FSBEI HE "A.i. Yedokimov Moscow State University of Medicine and Dentistry” of the Ministry of Health of the Russian Federation
- ООО "B. Braun Avitum Russland Clinics"
- ООО Medical Center "NEPHROS"
- ООО "St. Petersburg Dialysis Center"
- SPbSBHCI "City Hospital № 15"
- SHCI TR "Tula Regional Clinical Hospital"
- SI "St. Petersburg I.I. Dzhanelidze Research Institute of Emergency Medicine"
- ООО "Alliance Biomedical - Ural Group"
- ООО "Fresenius Medical Care Kuban"
- Krasnodar
- SBHCI RK "Republican Hospital.n.a. V.A. Baranov"
- BHCI OR "Regional Clinical Hospital"
- ООО "Dialysis Center"
- SBHCI "City Clinical Hospital № 24 of the Moscow Healthcare Department"
- FSBEI he "North-Western State Medical University n.a. I.I. Mechnikov" of the Ministry of Health of the Russian Federation
- ООО "В. Braun Avitum Russland Clinics"
- FSBEI he "Tver State Medical University" of the Ministry of Health of the Russian Federation
- SPbSBHCI "City Hospital of the Holy Reverend Martyr Elizabeth"
- SPbSBHCI "Mariinsky City Hospital"
- FSBI "Academician V.I. Shumakov Federal Scientific Center of Transplantology and Artificial Organs" of the Ministry of Health of the Russian Federation
- SPbSBHCI "City Clinical Hospital № 31"
- ООО "New Clinic"
- SBHCI NR "City Clinical Hospital № 2"
- Novosibirsk
- ООО "Nephroline-Novosibirsk"
- SPbSBHCI "Nikolaev Hospital"
- FSBEI HE "Kazan State Medical University Ministry" of the Ministry of Health of the Russian Federation
- ZAO "BIOCAD"
- Issue: No 4 (2018)
- Pages: 42-54
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/272828
- DOI: https://doi.org/10.18565/nephrology.2018.4.42-54
- ID: 272828
Cite item
Abstract
Keywords
Full Text
About the authors
V. Yu Shilo
FSBEI HE "A.i. Yedokimov Moscow State University of Medicine and Dentistry” of the Ministry of Health of the Russian Federation; ООО "B. Braun Avitum Russland Clinics"
Email: nephrolog@gmail.com
PhD in Medical Science, Associate Professor at the Department of Nephrology; medical director
V. P Babich
ООО Medical Center "NEPHROS"
G. V Vasilieva
ООО "St. Petersburg Dialysis Center"
K. A Vishnevsky
SPbSBHCI "City Hospital № 15"
T. A Gomova
SHCI TR "Tula Regional Clinical Hospital"
V. P Doru-Tovt
SI "St. Petersburg I.I. Dzhanelidze Research Institute of Emergency Medicine"
M. V Dudarev
ООО "Alliance Biomedical - Ural Group"
L. F Yeremeeva
ООО "Fresenius Medical Care Kuban"; Krasnodar
A. V Zuev
SBHCI RK "Republican Hospital.n.a. V.A. Baranov"
L. I Kotova
BHCI OR "Regional Clinical Hospital"
I. L Novoseltsev
ООО "Dialysis Center"
G. V Rodoman
SBHCI "City Clinical Hospital № 24 of the Moscow Healthcare Department"
V. Yu Ryasnyansky
FSBEI he "North-Western State Medical University n.a. I.I. Mechnikov" of the Ministry of Health of the Russian Federation
A. B Sabodash
ООО "В. Braun Avitum Russland Clinics"
A. V Solovyova
FSBEI he "Tver State Medical University" of the Ministry of Health of the Russian Federation
O. M Solovyova
SPbSBHCI "City Hospital of the Holy Reverend Martyr Elizabeth"
V. N Suchkov
SPbSBHCI "Mariinsky City Hospital"
A. G Strokov
FSBI "Academician V.I. Shumakov Federal Scientific Center of Transplantology and Artificial Organs" of the Ministry of Health of the Russian Federation
G. Yu Timokhovskaya
SPbSBHCI "City Clinical Hospital № 31"
V. M Chistyakov
ООО "New Clinic"
L. A Shpagina
SBHCI NR "City Clinical Hospital № 2"; Novosibirsk
L. A Fedotova
ООО "Nephroline-Novosibirsk"
N. G Khadikova
SPbSBHCI "Nikolaev Hospital"
E. V Khazova
FSBEI HE "Kazan State Medical University Ministry" of the Ministry of Health of the Russian Federation
M. A Morozova
ZAO "BIOCAD"
E. A Dokukina
ZAO "BIOCAD"
Yu. N Lin’kov
ZAO "BIOCAD"
References
- Хроническая болезнь почек и нефропротективная терапия. Методическое руководство для врачей. Под редакцией Е.М. Шилова. М.,2012:4. [Chronic kidney disease and nephroprotective therapy. Ed. by E.M. Shilov. Moscow, 2012. 4 р. (In Russ.)].
- McClellan W, Aronoff S.L., Bolton W.K., Hood S., Lorber D.L., Tang K.L., Tse T.F., Wasserman B., Leiserowitz M. The prevalence of anemia in patients with chronic kidney disease. Curr. Med. Res. Opin. 2004;20(9):1501-1510.
- Coyne D.W., Goldsmith D., Macdougal I. New options for the anemia of chronic kidney disease. Kidney International Supplements. 2017;7:157-163.
- Mikhail A., Brown С., Williams J. et al. Clinical Practice Guideline. Anaemia of Chronic Kidney Disease. 2017. оригинальные статьи
- http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf
- Kalantar-Zadeh K. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. Am. J. Nephrol. 2017;45:235-247. doi: 10.1159/000455387.
- Ряснянский В., Шостка Т. Нефрогенная анемия - индивидуальный подход к лечению. Врач. 2012;6:23-25.
- EMEA/H/C/000332/II/0035. Aranesp. Scientific discussion. http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_ Variation/human/000332/WC500026147.pdf
- European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). EMEA/CHMP/BMWP/301636/2008, 2010.
- Федеральный закон № 61-ФЗ от 12.04.2010 «Об обращении лекарственных средств».
- Национальный стандарт Российской Федерации ГОСТ Р. 52379-2005 «Надлежащая клиническая практика» (утв. Приказом Федерального агентства по техническому регулированию и метрологии от 27 сентября 2005 г. № 232-ст).
- Приказ от 19 июня 2003 г. N. 266 «Об утверждении правил клинической практики в Российской Федерации».
- Приказ от 01 апреля 2016 г. N. 200н «Об утверждении правил надлежащей клинической практики».
- Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010) U.S. Department of health and human services National Institutes of Health National Cancer Institute. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_ QuickReference_5x7.pdf
- Summary of the scientific discussion. Aranesp. Procedure No. EMEA/H/C/332/ II/28. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Scientific_Discussion_-_Variation/human/000332/WC500026146.pdf
- Shein-Chung Chow et al. Sample Size in Clinical Research. S.91.
- Lehana Thabane. Sample Size Determination in Clinical Trials. S.10.
- Tenny S., Gossman W.G. Evidence Based Medicine (EBM) [Updated 2018 May 13]. In: StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/ NBK470182/
- Шило В.Ю. Новый эритропоэз-стимулирующий препарат Аранесп (дарбэпоэтин альфа) в коррекции анемии почечного генеза. Нефрология и Диализ. 2007;3:216-223.